Azelnidipine, a new long-acting calcium-channel blocker, inhibits tumour necrosis factor-α-induced monocyte chemoattractant protein-1 expression in endothelial cells

Journal of International Medical Research

Volumn 34, Issue 6, 2006, Pages 671-675

  Matsui, T ^a   Yamagishi, Shoichi ^a   Nakamura, K ^a   Inoue, H ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Atherosclerosis; Azelnidipine; Dihydropyridine based calcium antagonists; Monocyte chemoattractant protein 1; Oxidative stress

Indexed keywords

AZELNIDIPINE; CALCIUM CHANNEL BLOCKING AGENT; LONG ACTING DRUG; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; INHIBITION KINETICS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UMBILICAL VEIN; UPREGULATION;

EID: 33846470610     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000603400613     Document Type: Article

References (25)

1. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
2. Introna M, Mantovani A: Early activaton signals in endothelial cells. Arterioscler Thromb Vasc Biol 1997; 17: 423-428.
3. Mantovani A, Bussolino F, Dejana E: Cytokine regulation of endothelial cell function, FASEB J 1992; 6: 2591-2599.
4. Vanden Berghe W, Vermeulen L, de Wilde G, De Bosscher K, Boone E, Haegeman G, et al: Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6. Biochem Pharmacol 2000; 60: 1185-1195.
5. Weiss JM, Cuff CA, Berman JW: TGF-beta downmodulates cytokine-induced monocyte chemoattractant protein (MCP)-1 expression in human endothelial cells. A putative role for TGF-beta in the modulation of TNF receptor expression. Endothelium 1999; 6: 291-302.
6. Nawroth PP, Stern DM: Modulation of endothelial cells hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740-745.
7. Taddei S, Virdis A, Ghiadoni L, Sudano J, Salvetti A: Antihypertensive drugs and reversing of endothelial dysfunction in hypertension. Curr Hypertens Rep 2000; 2: 64-70.
8. Taddei S, Virdis A, Ghiadoni L, Magagna A, Pasini AF, Garbin U, et al: Effect of calcium antagonist or beta blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients. J Hypertens 2001; 19: 1379-1386.
9. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, et al: Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002; 106: 2422-2427.
10. Mak IT, Weglicki WB. Antioxidant activity of calcium channel blocking drugs. Methods Enzymol 1994; 234: 620-630.
11. Kuramoto K, Ichikawa S, Hiral A, Kanada S, Nakachi T, Ogihara T: Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens Res 2003; 26: 201-208.
12. Yamagishi S, Inagaki Y, Nakamura K, Imaizumi T: Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties. J Cardiovasc Pharmacol 2004; 43: 724-730.
13. Yoram Y, Ahuva L: Azelnidipine (CS-905), a novel dihydropyridine calcium channel blocker with gradual onset and prolonged duration of action. Cardiovasc Drug Rev 1995; 13: 137-148.
14. Rollins BJ: Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. Mol Med Today 1996, 2: 198-204.
15. Yamagishi S, Inagaki Y, Kikuchi S: Nifedipine inhibits tumor necrosis factor-alpha-induced monocyte chemoattractant protein-1 overexpression by blocking NADPH oxidase-mediated reactive oxygen species generation. Drugs Exp Clin Res 2003; 29: 147-152.
16. Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchim M, et al: Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J Biol Chem 2002; 277: 20309-20315.
17. Hoogeveen RC, Morrison A, Boerwinkle E, Miles JS, Rhodes CE, Sharrett AR, et al: Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: atherosclerosis risk in communities study. Atherosclerosis 2005; 183: 301-317.
18. Deo R, Khera A, McGuire DK, Murphy SA, Meo Neto Jde P, Morrow PA, et al: Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J Am Coll Cardiol 2004; 44: 1812-1818.
19. Nelken NA, Coughlin SR, Gordon D, Wilcox JN: Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 1991; 88: 1121-1127.
20. Boring L, Gosling J, Cleary M, Charo IF: Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998; 394: 894-897.
21. Park SK, Yang WS, Han NJ, Lee SK, Ahn H, Lee IK, et al: Dexamethasone regulates AP-1 to repress TNF-alpha induced MCP-1 production in human glomerular endothelial cells. Nephrol Dial Transplant 2004; 19: 312-319.
22. Yamagishi S, Abe R, Inagaki Y, Nakamura K, Sugawara H, Inokuma D, et al: Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling. Am J Pathol 2004; 165: 1865-1874.
23. Yamagishi S, Inagaki Y, Nakamura K, Abe R, Shimizu T, Yoshimura A, et al: Pigment epithelium-derived factor inhibits TNF-alpha-induced interleukin-6 expression in endothelial cells by suppressing NADPH oxidase-mediated reactive oxygen species generation. J Mol Cell Cardiol 2004; 37: 497-506.
24. Yamagishi S, Matsui T, Nakamura K, Takeuchi M: Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced glycation end product-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation. Int J Tissue React 2005; 27: 189-195.
25. Griendling KK, Sorescu D, Ushio-Fukai M: NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86: 494-501.